Quality of Life in MS Patients Following MSC Therapy
Patient-Reported Outcomes — 12-month follow-up of quality of life improvements in multiple sclerosis patients receiving combined IV and intrathecal MSC protocols.
34
Patients Enrolled
RRMS and SPMS subtypes
12 Months
Follow-Up
Assessments at 3, 6, 12 mo
↓27%
EDSS Improvement
5.2 → 3.8 average reduction
No SAEs
Safety
Well-tolerated protocol
Study Overview
This patient-reported outcomes study followed 34 multiple sclerosis patients who received a combined intravenous (IV) and intrathecal WJ-MSC treatment protocol. The cohort included 22 patients with relapsing-remitting MS (RRMS) and 12 with secondary progressive MS (SPMS).
Outcomes were measured using the Expanded Disability Status Scale (EDSS), SF-36 health survey, and patient-reported symptom assessments. The dual-route administration was designed to maximize both systemic immunomodulation (IV) and direct CNS therapeutic effects (intrathecal).
EDSS Disability Score Progression
The Expanded Disability Status Scale (0–10) quantifies disability in MS. Lower scores indicate less disability.
Key Finding: 27% EDSS reduction — average score decreased from 5.2 to 3.8 at 12 months, crossing the clinically meaningful threshold of 1.0 point.
Quality of Life (SF-36)
Three key SF-36 domains tracked over 12 months (0–100, higher = better).
Physical
+17.2 pts (↑53%)
Mental
+20.2 pts (↑52%)
Vitality
+22.9 pts (↑80%)
Symptom-Specific Improvements
Patient-reported symptom severity scores (0–100) at baseline vs. 12 months.
| Symptom | Baseline | 12 Months | Improvement |
|---|---|---|---|
| Fatigue | 78 | 42 | ↓46% |
| Walking ability | 62 | 38 | ↓39% |
| Bladder function | 54 | 32 | ↓41% |
| Spasticity | 68 | 44 | ↓35% |
| Cognitive function | 48 | 30 | ↓38% |
| Pain levels | 72 | 40 | ↓44% |
Conclusion
Combined IV and intrathecal WJ-MSC therapy produced clinically meaningful improvements across all measured quality of life domains in MS patients. The 27% EDSS reduction, combined with substantial improvements in fatigue (46%), pain (44%), and bladder function (41%), demonstrates the multi-system benefits of this dual-route approach. Results were sustained at the 12-month follow-up.
Individual results may vary. Read our full medical disclaimer.
Considering MSC Therapy for Multiple Sclerosis?
Schedule a no-obligation consultation with our specialists to discuss treatment options.
Or call directly: +90 534 856 92 92